Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04320979

Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients

Postmastectomy Prophylactic Internal Mammary Nodal Irradiation for High-risk Patients With Non-metastatic Breast Cancer

Status
Active Not Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
2,400 (actual)
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
Sex
Female
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the impact of internal mammary nodal irradiation on disease-free survival in high-risk breast cancer patients treated with mastectomy or breast-conserving surgery.

Detailed description

Eligible patients are randomized into 2 groups: chest wall/whole breast and supraclavicular nodal +-axillary plus internal mammary nodal irradiation, and chest wall/whole breast and supraclavicular nodal +-axillary nodal irradiation. The prescription dose is 50 Gy in 25 fractions over 5 weeks or 43.5Gy in 15 fractions over 3 weeks. Breast cancer patients treated with breast-conserving surgery will receive tumor bed boost. During and after radiotherapy, the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.

Conditions

Interventions

TypeNameDescription
RADIATIONinternal mammary nodal irradiationchest wall/whole breast and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions). Patients treated with breast-conserving surgery will receive tumor bed boost. Concurrent boost (60 Gy in 25 fractions over 5 weeks or 49.5 Gy in 15 fractions over 3 weeks) or sequential boost (10 Gy in 5 fractions over 1 week or 8.7 Gy in 3 fractions over 3 days) is optional.
RADIATIONno internal mammary nodal irradiationchest wall/whole breast and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions). Concurrent boost (60 Gy in 25 fractions over 5 weeks or 49.5 Gy in 15 fractions over 3 weeks) or sequential boost (10 Gy in 5 fractions over 1 week or 8.7 Gy in 3 fractions over 3 days) is optional.

Timeline

Start date
2020-05-08
Primary completion
2025-11-01
Completion
2030-05-01
First posted
2020-03-25
Last updated
2026-01-13

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04320979. Inclusion in this directory is not an endorsement.